Search Results
42 Results Found for “Cardiometabolic syndrome”
In response to the increasing prevalence of obesity, the consumption of high-calorie and high-sugar foods and an unprecedented aging population, type 2 diabetes (T2D) continues to rise globally. The International Diabetes Federation reported that 589 million individuals aged 20 to 79 years had ...
Data presented at ENDO 2026 highlighted investigational approaches for difficult-to-control type 2 diabetes and acquired hypothalamic obesity, real-world outcomes with tirzepatide, and wider health impacts of GLP-1-based therapy.
Welcome to the summer 2026 issue of touchREVIEWS in Endocrinology. In this issue, we bring together articles that reflect the evolving complexity of endocrine and metabolic disease, while highlighting the growing importance of patient-centred care, translational science and interdisciplinary management. We ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1RA-based therapies are currently considered to be one of the most attractive classes of medications for managing type 2 diabetes (T2D) because of their impressive weight loss properties, glycated haemoglobin (HbA1c) ...
Urinary lithogenesis processes are activated in patients with obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D). This is a relatively unfamiliar topic among endocrinologists. Beyond the epidemiological evidence accumulated over the recent years, the purpose of this paper is ...
The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has increased over the past three decades and is estimated to be 30% as of 2022.1Â As an indication of disease burden, MASLD-related liver transplantation has already surpassed many other aetiologies as ...
Insulin resistance (IR), a hallmark of various metabolic disorders, represents a diminished responsiveness of target tissues to the actions of insulin, resulting in impaired glucose uptake, dyslipidaemia and endothelial dysfunction.1,2 Worldwide, the prevalence of IR among adults ranges from 15.5% to 46.5%.3–5 ...
GLP-1 receptor agonists have been a standout development this year, reshaping the treatment of type 2 diabetes and obesity. In this expert perspective, Glenn D Braunstein highlights their expanding benefits, from weight loss and cardiometabolic protection to emerging dual- and tri-agonist therapies, while also addressing key challenges as these agents move rapidly into mainstream clinical practice.
ObesityWeek® 2025 highlighted obesity as a chronic, multi-system disease that links cardiovascular, renal, and metabolic health. New data from clinical trials showcased therapies improving weight, blood pressure, and inflammation, signalling a shift toward integrated care where obesity management becomes central to cardiovascular-kidney-metabolic health.
Gestational diabetes (GD) is a heterogeneous disorder that arises when pancreatic insulin secretion fails to compensate for the insulin resistance of pregnancy. A disbalance in either component, insufficient secretion or excessive resistance, can lead to GD and reflects its variable ...
The metabolic syndrome (MetS) construct, while valuable for middle-aged populations, shows critical limitations when applied to older adults. Traditional criteria emphasizing waist circumference, blood pressure, lipids and glucose fail to capture the complex interplay between ageing physiology and metabolic dysfunction.1,2 ...
This Q&A with Dr Paul Brennan offers a practical guide to the diagnosis and management of metabolic dysfunction-associated steatohepatitis (MASH). Covering key risk factors, non-invasive diagnostic tools, lifestyle strategies, and emerging therapies, it provides clinicians with clear approaches to early detection and comprehensive patient care.
As we continue advancing the field of endocrinology, I’m excited to spotlight the impactful work being done by the American Association of Clinical Endocrinology (AACE). Our mission is to elevate the practice of clinical endocrinology to improve global health. ...
Polycystic ovary syndrome (PCOS) is a complex, multisystemic condition characterized by reproductive, metabolic and dermatologic manifestations, including hyperandrogenism and ovulatory dysfunction. Despite its prevalence and significant impact on quality of life, PCOS remains underdiagnosed and poorly managed due to its ...
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age and is characterized by hyperandrogenism, anovulation and insulin resistance (IR).1Â Women with PCOS have a high risk of developing type 2 diabetes (T2D), dyslipidaemia, hypertension and ...
Tirzepatide is a first-in-class novel dual glucose-dependent insulinotropic peptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist (twincretin), formulated as a synthetic peptide containing 39 amino acids based on the native GIP.1Â Tirzepatide has a GIP receptor-binding affinity comparable with native GIP and ...
Type 2 diabetes (T2D) continues to pose an ever-greater global health challenge, with 1.31 billion individuals predicted to be living with diabetes globally by 2050; the majority of whom will have T2D.1Â Closely linked to T2D is metabolic dysfunction-associated steatotic ...
The incidence of youth-onset type 2 diabetes (T2D) is increasing.1,2 Growing evidence has demonstrated that youth-onset T2D is rapidly progressive, with earlier onset of life-limiting complications compared with adult-onset T2D.3,4Â Initiation of effective treatment that can restore beta ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
